鲁拉西酮
5-羟色胺能
精神分裂症(面向对象编程)
抗精神病药
5-羟色胺受体
血清素
精神分裂症的治疗
精神病
医学
丁螺环酮
非定型抗精神病薬
药理学
心理学
受体
精神科
内科学
作者
Andrew C. McCreary,Adrian Newman‐Tancredi
标识
DOI:10.2174/1381612821666150605105215
摘要
Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT1A agonists on neurogenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI